Evidence map›Paper›PMID 30949885›Full record

ArticleCancer causes & control : CCC2019

Diabetes and differences in detection of incident invasive breast cancer.

Gregory S Calip, Onchee Yu, Denise M Boudreau, Huibo Shao, Ruth Oratz, Stephen B Richardson, Heather T Gold

Abstract read
In one paragraph

Article in Cancer causes & control : CCC, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gregory S CalipCenter for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois at Chicago, 833 South Wood Street MC 871, Chicago, IL, 60612, USA. gcalip@uic.edu.ORCID http://orcid.org/0000-0002-7744-3518
Onchee YuKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Denise M BoudreauKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Huibo ShaoBaptist Memorial Health Care, Germantown, TN, USA.
Ruth OratzDepartment of Medicine, New York University School of Medicine, New York, NY, USA.
Stephen B RichardsonDepartment of Medicine, New York University School of Medicine, New York, NY, USA.
Heather T GoldDepartment of Population Health, New York University School of Medicine, New York, NY, USA.

Funding

Institutional Career DevelopmentKL2TR002002 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PHILLIPS, SHANE A · 2016 to 2024
$6.8M
Commonly Used Medications and Breast Cancer RecurrenceR01CA120562 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI BOUDREAU, DENISE M · 2007 to 2011
$2.1M
Treatment and Outcomes in Diabetic Breast Cancer PatientsR01CA188353 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GOLD, HEATHER TAFFET · 2015 to 2018
$1.4M
Center for Clinical and Translational ScienceKL2TR000048 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI AZAR, DIMITRI T, MERMELSTEIN, ROBIN J. · 2012 to 2014
$559k
National Cancer Institute R01CA120562National Cancer Institute R01CA188353National Center for Advancing Translational Sciences KL2TR002002NCATS NIH HHS KL2 TR000048NCATS NIH HHS KL2 TR002002NCI NIH HHS R01 CA120562NCI NIH HHS R01 CA188353
6 · The paper itself

Abstract

Many women diagnosed with breast cancer have chronic conditions such as diabetes that may impact other health behaviors. Our purpose was to determine if breast cancer screening and detection differs among women with and without diabetes. We conducted a cross-sectional analysis of a retrospective cohort of women aged 52-74 years diagnosed with incident stages I-III breast cancer enrolled in an integrated health plan between 1999 and 2014 with linkage to the Surveillance, Epidemiology and End Results registry (n = 2040). Screening data were taken from electronic health records. We used multivariable modified Poisson regression models with robust standard errors to estimate relative risks (RR) and 95% confidence intervals (CI) for outcomes of (i) receipt of screening in the 2 years prior to diagnosis; (ii) symptom-detected breast cancer; and (iii) diagnosis of locally advanced stage III breast cancer. Compared to women without diabetes, women with diabetes were similar with respect to receipt of screening mammography (78% and 77%), symptom-detected breast cancer (46% and 49%), and stage III diagnosis (7% and 7%). In multivariable models adjusting for age and year of diagnosis, race, BMI, Charlson comorbidity score and depression diagnosis no differences were observed in the outcomes by presence of diabetes. Further investigation is warranted to determine how diabetes acts as a mediating factor in adverse breast cancer outcomes.

Indexed as

AgedBreast NeoplasmsCohort StudiesComorbidityCross-Sectional StudiesDiabetes MellitusEarly Detection of CancerFemaleHumansMammographyMass ScreeningMiddle AgedNeoplasm StagingRacial GroupsRetrospective StudiesBreast cancerCancer screeningDiabetesMammography

Identifiers

PMID30949885
PMCPMC6467528

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.